The Gut-Brain Axis in Neurodegeneration: Mechanistic Insights and Emerging Therapeutic Perspectives
Clicks: 1
ID: 314150
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #236 of 254 articles by views in Yemen Journal of Medicine
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The gut-brain axis (GBA) is an intricate, bidirectional communication network connecting the central nervous system (CNS) and gastrointestinal tract (GIT) via neural, immune, endocrine, and metabolic pathways. This dynamic interaction, modulated by the gut microbiota, influences essential physiological and cognitive functions, including mood regulation, stress response, and neuronal signaling. Dysbiosis, an imbalance in gut microbial composition, contributes to neurodegenerative disorders (NDDs) such as Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) by promoting inflammation and neuroinflammation, oxidative stress, neurotransmitter production and regulation, bloodbrain barrier integrity, protein aggregation, and misfolding. Microbial metabolites, such asshort-chain fatty acids (SCFAs), bile acids, and tryptophan derivatives, play a crucial role in maintaining CNS homeostasis, whereas neurotoxic metabolites, like trimethylamine N-oxide (TMAO), exacerbate neurodegenerative pathology. Therapeutic interventions, including dietary modulation, prebiotics, probiotics, psychobiotics, fecal microbiota transplantation (FMT), vagus nerve stimulation (VNS), and small-molecule modulators, represent promising approaches to restore GBA balance and delay neurodegeneration. However, challenges remain in translating preclinical evidence into human application due to interindividual microbiome variability and limited mechanistic understanding. Emerging methodologies such as organ-on-a-chip models, wearable biosensors, and artificial intelligence-driven microbiome analytics hold potential for personalized, microbiota-based therapies. Standardization of biomarkers and study protocols will be essential to further clarify the GBA’s mechanistic involvement and therapeutic potential in neurodegenerative disease management.
| Reference Key |
2026gutbrain
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Harsha Marathe, Aarti Darade, Manoj Mahajan, Aman Upaganlawar, Chandrashekhar Upasani |
| Journal | Yemen Journal of Medicine |
| Year | 2026 |
| DOI |
10.63475/yjm.v5i1.0295
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.